360 related articles for article (PubMed ID: 18549841)
1. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Lu Z; Kou W; Du B; Wu Y; Zhao S; Brusco OA; Morgan JM; Capuzzi DM; ; Li S
Am J Cardiol; 2008 Jun; 101(12):1689-93. PubMed ID: 18549841
[TBL] [Abstract][Full Text] [Related]
2. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
[TBL] [Abstract][Full Text] [Related]
3. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
Clin Exp Hypertens; 2010; 32(8):491-8. PubMed ID: 21091365
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Zhao SP; Peng DQ; Yu BL; Huo Y;
Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
[TBL] [Abstract][Full Text] [Related]
6. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
Ann Med; 2010 Apr; 42(3):231-40. PubMed ID: 20350253
[TBL] [Abstract][Full Text] [Related]
7. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
Zhao SP; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC; Liu L; Ye HJ; Wu ZH;
J Cardiovasc Pharmacol; 2007 Feb; 49(2):81-4. PubMed ID: 17312447
[TBL] [Abstract][Full Text] [Related]
8. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina.
Li JJ; Hu SS; Fang CH; Hui RT; Miao LF; Yang YJ; Gao RL
Clin Chim Acta; 2005 Feb; 352(1-2):217-24. PubMed ID: 15653117
[TBL] [Abstract][Full Text] [Related]
9. [China coronary secondary prevention study (CCSPS)].
Lu ZL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):109-15. PubMed ID: 15924803
[TBL] [Abstract][Full Text] [Related]
10. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
11. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics.
Ong HT; Cheah JS
Chin Med J (Engl); 2008 Aug; 121(16):1588-94. PubMed ID: 18982874
[TBL] [Abstract][Full Text] [Related]
12. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
Moriarty PM; Roth EM; Karns A; Ye P; Zhao SP; Liao Y; Capuzzi DM; Bays HE; Zhang F; Liu S; Reichman AJ; Brusco OA; Lu G; Lerman S; Duan Z; Guo S; Liu PL; Zhao J; Zhang Y; Li S
J Clin Lipidol; 2014; 8(6):568-575. PubMed ID: 25499939
[TBL] [Abstract][Full Text] [Related]
13. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
[TBL] [Abstract][Full Text] [Related]
14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
15. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program).
Nagashima M; Koyanagi R; Kasanuki H; Hagiwara N; Yamaguchi J; Atsuchi N; Honda T; Haze K; Sumiyoshi T; Urashima M; Ogawa H;
Am J Cardiol; 2007 Jun; 99(11):1523-8. PubMed ID: 17531574
[TBL] [Abstract][Full Text] [Related]
16. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
17. [The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial].
DU BM; Lu ZL; Chen Z; Wu YF
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):890-4. PubMed ID: 17217713
[TBL] [Abstract][Full Text] [Related]
18. [China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].
Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1067-70. PubMed ID: 16563271
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
[TBL] [Abstract][Full Text] [Related]
20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
